Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Cerilliant
Cipla
US Army
Johnson and Johnson
Boehringer Ingelheim
Fuji
Baxter
Queensland Health

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,245,766

« Back to Dashboard

Which drugs does patent 6,245,766 protect, and when does it expire?

Patent 6,245,766 protects GEODON and is included in two NDAs.

This patent has fourteen patent family members in fourteen countries.
Summary for Patent: 6,245,766
Title: Method of treating psychiatric conditions
Abstract:A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
Inventor(s): Watsky; Eric J. (Stonington, CT)
Assignee: Pfizer Inc (New York, NY)
Application Number:09/216,334
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,245,766

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-001 Feb 5, 2001 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF BIPOLAR DISORDER ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-002 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF BIPOLAR DISORDER ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-003 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF BIPOLAR DISORDER ➤ Sign Up
Pfizer GEODON ziprasidone hydrochloride CAPSULE;ORAL 020825-004 Feb 5, 2001 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF BIPOLAR DISORDER ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Teva
QuintilesIMS
Argus Health
Covington
Express Scripts
Federal Trade Commission
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.